%0 Journal Article
%T Association Between Asthma Exacerbations and Lung Function With Reslizumab Treatment In Patients With Uncontrolled Eosinophilic Asthma: Pooled Analysis of Two Phase 3 Trials
%A John M. Fahrenholz
%A Margaret Garin
%A Mirna McDonald
%J Journal of Allergy and Clinical Immunology
%D 2018
%R 10.1016/j.jaci.2017.12.052
%X Reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly
reduced the risk of clinical asthma exacerbation (CAE) in patients with inadequately
controlled eosinophilic asthma and ¡Ý1 CAE in the prior 12 months, with greater treatment
effect in patients with more historical CAEs. The objective of this analysis was to
assess the association between baseline CAE rate and lung function (FEV1 change from
baseline).
%U https://www.jacionline.org/article/S0091-6749(17)31952-8/abstract